These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7537190)

  • 1. User acceptability of an alpha-fetoprotein screening programme.
    Jørgensen FS
    Dan Med Bull; 1995 Feb; 42(1):100-5. PubMed ID: 7537190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Attitude of pregnant women to prenatal screening].
    Jørgensen FS
    Ugeskr Laeger; 1996 Sep; 158(39):5447-52. PubMed ID: 8928256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine assessment of amniotic fluid alpha-Fetoprotein in early second-trimester amniocentesis is no longer justified.
    Widlund KF; Gottvall T
    Acta Obstet Gynecol Scand; 2007; 86(2):167-71. PubMed ID: 17364279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse pregnancy outcomes after a false-positive second trimester serum screen for Down syndrome in Thai pregnant women.
    Sritippayawan S; Vachirasrisoontra C
    J Med Assoc Thai; 2005 Apr; 88(4):449-54. PubMed ID: 16146246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.
    Lynge E
    APMIS Suppl; 1998; 83():1-44. PubMed ID: 9850674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetal fibronectin test predicts delivery before 30 weeks of gestation in high risk women, but increases anxiety.
    Shennan A; Jones G; Hawken J; Crawshaw S; Judah J; Senior V; Marteau T; Chinn S; Poston L
    BJOG; 2005 Mar; 112(3):293-8. PubMed ID: 15713142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal screening for congenital nephrosis in east Finland: results and impact on the birth prevalence of the disease.
    Heinonen S; Ryynänen M; Kirkinen P; Penttilä I; Syrjänen K; Seppälä M; Saarikoski S
    Prenat Diagn; 1996 Mar; 16(3):207-13. PubMed ID: 8710773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Participation behaviour following a false positive test in the Copenhagen mammography screening programme.
    Andersen SB; Vejborg I; von Euler-Chelpin M
    Acta Oncol; 2008; 47(4):550-5. PubMed ID: 18465321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychological outcomes following maternal serum screening: a cohort study.
    Goel V; Glazier R; Summers A; Holzapfel S
    CMAJ; 1998 Sep; 159(6):651-6. PubMed ID: 9780964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal serum alpha-fetoprotein screening programs and quality control for laboratories performing maternal serum and amniotic fluid alpha-fetoprotein assays: policy statement. American Society of Human Genetics.
    CMAJ; 1987 Jun; 136(12):1253-6. PubMed ID: 2438025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers.
    Wald NJ; Morris JK; Ibison J; Wu T; George LM
    Prenat Diagn; 2006 Jun; 26(6):559-64. PubMed ID: 16700087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prenatal maternal blood screening for the detection of fetal chromosomal abnormalities: clinical importance of the rate of false positives].
    Alvarez-Nava F; Soto M; Padrón T; Morales A; Villalobos D; Rojas de Atencio A; Prieto M; Martínez MC
    Invest Clin; 2003 Sep; 44(3):195-207. PubMed ID: 14552058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenatal diagnosis using the triple test.
    Palka G; Guanciali Franchi P; Papponetti M; Marcuccitti J; Morizio E; Calabrese G; Stuppia L; Di Ilio C
    Minerva Ginecol; 1998 Oct; 50(10):411-5. PubMed ID: 9866951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal screening for Down syndrome: the problem of recurrent false-positives.
    Wald NJ; Huttly WJ; Rudnicka AR
    Prenat Diagn; 2004 May; 24(5):389-92. PubMed ID: 15164416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient acceptance of prenatal alpha-fetoprotein screening: a preliminary study.
    Sikkink J
    Fam Pract Res J; 1990; 10(2):123-31. PubMed ID: 1705075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein.
    Wenstrom KD; Owen J; Davis RO; Brumfield CG
    Obstet Gynecol; 1996 Feb; 87(2):213-6. PubMed ID: 8559526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes to prenatal testing and notification for HIV infection in Nairobi, Kenya.
    Marjan RS; Ruminjo JK
    East Afr Med J; 1996 Oct; 73(10):665-9. PubMed ID: 8997847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong.
    Lam YH; Ghosh A; Tang MH; Tang LC; Lee CP; Sin SY; Ho PK
    Prenat Diagn; 1998 Jun; 18(6):585-89. PubMed ID: 9664604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.